Ftse Mib
36.143,15
0,23%
DAX
21.283,45
1,15%
S&P 500
6.049,24
0,88%
NASDAQ
19.756,78
0,64%
Bitcoin
105.160,78
-0,95%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xeris Biopharma Holdings Inc (XERS) Xeris Biopharma Holdings Inc (XERS) Notizie

Xeris Biopharma Holdings Inc

XERS
3,34
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 11:53:22
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
21/1/202515:00PRNUSThe American Diabetes Association and Xeris Pharmaceuticals..
10/1/202513:17EDGAR2Form 8-K - Current report
10/1/202513:00BWXeris Expects to Exceed Full-Year 2024 Financial Guidance
07/1/202522:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/1/202522:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:15BWXeris Announces Inducement Grants Under NASDAQ Listing Rule..
26/11/202413:00BWXeris to Participate in Piper Sandler 36th Annual Healthcare..
08/11/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202413:13EDGAR2Form 8-K - Current report
08/11/202413:00BWXeris Biopharma Reports Third Quarter 2024 Financial Results
31/10/202413:00BWXeris Biopharma to Report Third Quarter 2024 Financial..
04/10/202422:05BWXeris Announces Inducement Grants Under NASDAQ Listing Rule..
22/8/202413:00BWXeris to Participate in Upcoming Investor Conferences
09/8/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202422:27EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/8/202413:15EDGAR2Form 8-K - Current report
08/8/202413:00BWXeris Biopharma Reports Second Quarter 2024 Financial..
02/8/202423:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202423:16EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/8/202422:14EDGAR2Form 8-K - Current report
25/7/202413:00BWXeris Biopharma to Report Second Quarter 2024 Financial..
08/7/202413:14EDGAR2Form 8-K - Current report
08/7/202413:00BWXeris Biopharma Announces CEO Succession Plan
03/7/202419:05BWXeris Announces Inducement Grants Under NASDAQ Listing Rule..
05/6/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202422:15EDGAR2Form 8-K - Current report
03/6/202413:00BWXeris Presents New Post Hoc Analysis on Effects of..
30/5/202413:30BWXeris Biopharma Announces Positive Topline Phase 2 Clinical..
30/5/202413:00BWXeris to Participate in the Jefferies Global Healthcare..
09/5/202413:14EDGAR2Form 8-K - Current report
09/5/202413:00BWXeris Biopharma Reports First Quarter 2024 Financial Results..
06/5/202413:00BWXeris Enters Into an Exclusive Worldwide Collaboration and..
02/5/202413:00BWXeris Biopharma to Report First Quarter 2024 Financial..
03/4/202422:05BWXeris Pharmaceuticals Announces Inducement Grants Under..
02/4/202413:00BWXeris Biopharma to Participate in the 23rd Annual Needham..
06/3/202422:19EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/3/202422:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/3/202413:27EDGAR2Form 8-K - Current report
06/3/202413:02BWXeris Biopharma Reports Fourth Quarter and Full Year 2023..
06/3/202413:00BWXeris Refinances Its $150M Senior Secured Term Loan Facility..
28/2/202413:00BWXeris Biopharma to Report Fourth Quarter and Full Year 2023..
05/2/202413:00BWXeris to Present at the Oppenheimer 34th Annual Healthcare..
31/1/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: Min: Max:
Chiusura: 3,34

La tua Cronologia

NASDAQ
XERS
Xeris Biopharma
LSE
RWS
Rws
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network